Payer Agreements Discussed in New FirstWord Report Recently Published at MarketPublishers.com
25 Nov 2011 • by Natalie Aster
LONDON – With tightening budgets and the contraction of payer funding for new products, it is getting more and more problematic for pharmaceutical companies to gain an access to the market.
Across the UK, the US, Canada, Australia and some European nations, payer schemes are becoming a common practice. Schemes advanced by pharmaceutical companies either aim to grapple financial issues such as price volume agreements, or they tackle uncertainty by addressing increased data collection. And the question arises – What are the key features that will ensure success?
New market research report “Payer Agreements: Splitting the Risk” worked out by FirstWord offers a complete and concise overview of payer schemes by definition and category.
- detailed examination of the role of agreements in global pricing, reimbursement and market access;
- discussion of the drivers for schemes, including health technology assessment (HTA) and financial challenges;
- illustration of country-by-country trends along with case studies;
- expert insight into the role of schemes and their evolution;
- analysis of the pros and cons of agreements.
Title: Payer Agreements: Splitting the Risk
Published: October, 2011
Price: US$ 695
CURRENT AGREEMENTS WITH PAYERS ACROSS AUSTRALIA, EUROPE, CANADA AND THE US
Defining and categorizing schemes
Definitions from the literature
UK definition and categorization
Drivers for schemes
HTA and saying no
Dealing with uncertainty
COUNTRY TRENDS IN SCHEMES AND SELECTED CASE STUDIES
Bosentan patient registry
Clozaril money-back guarantee
No cure, no pay for Diovan
Aclasta refund scheme
Tarceva discount scheme
Sutent discount scheme
Avastin, Erbitux and MabCampath rebate schemes
Crestor and ezetimibe coverage with evidence development
Multiple Sclerosis Risk Sharing Scheme
Velcade money back guarantee
Lucentis dose capping scheme
Proscar refund scheme
Zocor refund scheme
Januvia guarantee scheme
Sanofi and Proctor & Gamble pay for fractures scheme
POTENTIALS AND PITFALLS OF AGREEMENTS
Fit with pricing and reimbursement environments
Pros and cons
Too early to say
Maybe necessary, but not sufficient
Exploring uncertainty, not discounting in the future
More new research reports by the publisher can be found at FirstWord page.
The Market Publishers, Ltd.
Tel: +44 208 144 6009
Fax: +44 207 900 3970